• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    5/8/23 1:35:23 PM ET
    $ABBV
    $AVDL
    $CTLT
    $IBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    ISEE CALL TRADE BULLISH 09/15/23 $40.00 $225.0K 34.8K 7.2K
    TMCI PUT SWEEP BEARISH 05/19/23 $22.50 $34.6K 5 2.2K
    IMGN CALL SWEEP BULLISH 01/19/24 $11.00 $52.0K 354 1.5K
    CTLT PUT SWEEP BEARISH 05/19/23 $35.00 $49.7K 2.7K 1.3K
    IBRX CALL SWEEP BEARISH 10/20/23 $2.50 $36.5K 2.1K 892
    AVDL CALL TRADE BULLISH 06/16/23 $10.00 $137.5K 11.2K 330
    RETA CALL SWEEP BULLISH 05/12/23 $105.00 $149.9K 541 316
    SYK CALL SWEEP NEUTRAL 09/15/23 $300.00 $28.5K 737 149
    MRTX CALL SWEEP BULLISH 05/19/23 $40.00 $50.3K 149 148
    ABBV CALL SWEEP BEARISH 05/19/23 $145.00 $31.5K 555 108

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • Regarding ISEE (NASDAQ:ISEE), we observe a call option trade with bullish sentiment. It expires in 130 day(s) on September 15, 2023. Parties traded 5000 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $225.0K, with a price of $45.0 per contract. There were 34833 open contracts at this strike prior to today, and today 7203 contract(s) were bought and sold.

    • Regarding TMCI (NASDAQ:TMCI), we observe a put option sweep with bearish sentiment. It expires in 11 day(s) on May 19, 2023. Parties traded 633 contract(s) at a $22.50 strike. This particular put needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $55.0 per contract. There were 5 open contracts at this strike prior to today, and today 2263 contract(s) were bought and sold.

    • For IMGN (NASDAQ:IMGN), we notice a call option sweep that happens to be bullish, expiring in 256 day(s) on January 19, 2024. This event was a transfer of 100 contract(s) at a $11.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $52.0K, with a price of $520.0 per contract. There were 354 open contracts at this strike prior to today, and today 1504 contract(s) were bought and sold.

    • For CTLT (NYSE:CTLT), we notice a put option sweep that happens to be bearish, expiring in 11 day(s) on May 19, 2023. This event was a transfer of 181 contract(s) at a $35.00 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $49.7K, with a price of $275.0 per contract. There were 2776 open contracts at this strike prior to today, and today 1374 contract(s) were bought and sold.

    • Regarding IBRX (NASDAQ:IBRX), we observe a call option sweep with bearish sentiment. It expires in 165 day(s) on October 20, 2023. Parties traded 96 contract(s) at a $2.50 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $36.5K, with a price of $381.0 per contract. There were 2114 open contracts at this strike prior to today, and today 892 contract(s) were bought and sold.

    • For AVDL (NASDAQ:AVDL), we notice a call option trade that happens to be bullish, expiring in 39 day(s) on June 16, 2023. This event was a transfer of 250 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $137.5K, with a price of $550.0 per contract. There were 11204 open contracts at this strike prior to today, and today 330 contract(s) were bought and sold.

    • For RETA (NASDAQ:RETA), we notice a call option sweep that happens to be bullish, expiring in 4 day(s) on May 12, 2023. This event was a transfer of 243 contract(s) at a $105.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $149.9K, with a price of $630.0 per contract. There were 541 open contracts at this strike prior to today, and today 316 contract(s) were bought and sold.

    • For SYK (NYSE:SYK), we notice a call option sweep that happens to be neutral, expiring in 130 day(s) on September 15, 2023. This event was a transfer of 24 contract(s) at a $300.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $28.5K, with a price of $1190.0 per contract. There were 737 open contracts at this strike prior to today, and today 149 contract(s) were bought and sold.

    • Regarding MRTX (NASDAQ:MRTX), we observe a call option sweep with bullish sentiment. It expires in 11 day(s) on May 19, 2023. Parties traded 69 contract(s) at a $40.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $50.3K, with a price of $730.0 per contract. There were 149 open contracts at this strike prior to today, and today 148 contract(s) were bought and sold.

    • For ABBV (NYSE:ABBV), we notice a call option sweep that happens to be bearish, expiring in 11 day(s) on May 19, 2023. This event was a transfer of 100 contract(s) at a $145.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $31.5K, with a price of $314.0 per contract. There were 555 open contracts at this strike prior to today, and today 108 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $AVDL
    $CTLT
    $IBRX

    CompanyDatePrice TargetRatingAnalyst
    ImmunityBio Inc.
    $IBRX
    3/12/2026$13.00Buy
    BTIG Research
    AbbVie Inc.
    $ABBV
    2/25/2026$260.00Outperform
    RBC Capital Mkts
    Stryker Corporation
    $SYK
    2/20/2026Outperform
    William Blair
    AbbVie Inc.
    $ABBV
    2/20/2026$275.00Overweight
    Barclays
    Stryker Corporation
    $SYK
    1/27/2026$387.00Hold
    TD Cowen
    AbbVie Inc.
    $ABBV
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    AbbVie Inc.
    $ABBV
    1/7/2026$240.00Neutral
    UBS
    Stryker Corporation
    $SYK
    1/6/2026$418.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $ABBV
    $AVDL
    $CTLT
    $IBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/4/25 6:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Director Palczuk Linda bought $39,640 worth of Ordinary Shares (5,000 units at $7.93), increasing direct ownership by 8% to 67,900 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/22/25 4:13:34 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thornton Peter J. bought $80,450 worth of Ordinary Shares (10,000 units at $8.04), increasing direct ownership by 11% to 104,055 units (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    1/14/25 4:24:12 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVDL
    $CTLT
    $IBRX
    SEC Filings

    View All

    SEC Form 8-K filed by Stryker Corporation

    8-K - STRYKER CORP (0000310764) (Filer)

    3/12/26 5:09:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Stryker Corporation

    8-K - STRYKER CORP (0000310764) (Filer)

    3/11/26 5:24:57 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form PRE 14A filed by AbbVie Inc.

    PRE 14A - AbbVie Inc. (0001551152) (Filer)

    3/9/26 4:31:02 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVDL
    $CTLT
    $IBRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form

    10/17/24 1:29:31 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SKYRIZI issued to ABBVIE INC

    Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:

    6/21/24 4:38:17 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVDL
    $CTLT
    $IBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research resumed coverage on ImmunityBio with a new price target

    BTIG Research resumed coverage of ImmunityBio with a rating of Buy and set a new price target of $13.00

    3/12/26 8:52:16 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RBC Capital Mkts initiated coverage on AbbVie with a new price target

    RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00

    2/25/26 7:48:26 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Stryker

    William Blair initiated coverage of Stryker with a rating of Outperform

    2/20/26 8:25:36 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $ABBV
    $AVDL
    $CTLT
    $IBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Treace John T. covered exercise/tax liability with 7,083 shares, decreasing direct ownership by 0.10% to 7,004,550 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/11/26 9:00:04 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Hair Mark covered exercise/tax liability with 4,659 shares, decreasing direct ownership by 0.54% to 863,549 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/11/26 9:00:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Chief Legl & Comp Off, CorpSec Elder Scot Michael covered exercise/tax liability with 1,850 shares, decreasing direct ownership by 0.23% to 794,936 units (SEC Form 4)

    4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

    3/11/26 9:00:07 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    $ABBV
    $AVDL
    $CTLT
    $IBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

    Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1. ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive Cancer Network (NCCN®) has updated its 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary-only disease. This update expands previous NCCN clinical guideline r

    3/17/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

    New York, NY, March 13, 2026 (GLOBE NEWSWIRE) -- New York Plastic Surgical Group (NYPS Group) and Deep Blue Med Spa (DBMS) are proud to announce that they have once again been recognized by Allergan Aesthetics as the #1 provider in New York State, marking the second consecutive year earning this distinction. In addition, the practices have been ranked Top 50 in the nation for 2026, placing them among an elite group of aesthetic providers across the United States. This recognition reflects NYPS Group and Deep Blue Med Spa's continued leadership in aesthetic medicine and their longstanding commitment to delivering advanced, evidence-based treatments performed by highly trained medical profe

    3/13/26 9:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVDL
    $CTLT
    $IBRX
    Leadership Updates

    Live Leadership Updates

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    Stryker showcases continued innovation across orthopaedics at AAOS 2026 Annual Meeting

    Evolving technologies and offerings reinforce commitment to shaping the future of orthopaedic care PORTAGE, Mich., March 3, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases its commitment to innovation across orthopaedic specialties with the introduction of the newest additions to the Triathlon® Total Knee System, the expanded Mako SmartRobotics™ portfolio and continued evolution of the power tool portfolio at the American Academy of Orthopaedic Surgeons' (AAOS) 2026 Annual Meeting in New Orleans. Triathlon Gold: Building on the legacy

    3/3/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ABBV
    $AVDL
    $CTLT
    $IBRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catalent Inc.

    SC 13G/A - Catalent, Inc. (0001596783) (Subject)

    11/14/24 4:35:03 PM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Treace Medical Concepts Inc.

    SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

    11/14/24 3:38:23 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalent Inc.

    SC 13G/A - Catalent, Inc. (0001596783) (Subject)

    11/14/24 9:50:26 AM ET
    $CTLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AVDL
    $CTLT
    $IBRX
    Financials

    Live finance-specific insights

    View All

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results

    PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared to the prior year.Reported fourth quarter 2025 net loss of $(9.4) million and adjusted EBITDA of $6.2 million in the fourth quarter 2025. Reported full-year 2025 net loss of $(59.0) million c

    2/27/26 7:05:00 AM ET
    $TMCI
    Medical/Dental Instruments
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care